Decide at what price you'd be comfortable buying and we'll help you stay ready.
Ibiden’s multi-year results show earnings that move with revenue and operating leverage, while substantial plant investment makes free cash flow sensitive to capital spending and working capital. Its reported cash balances provide funding capacity, although cash generation varies considerably across periods.
The latest quarter extended the improvement in revenue and operating profitability, while free cash flow also rebounded. However, a large positive working-capital contribution boosted cash from operations, so the quarter does not yet establish a durable change in cash conversion; capacity investment remains part of the financial profile.
Whether operating cash flow remains supportive of free cash flow as the positive working-capital contribution changes and capacity spending proceeds.
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 266.5B | 300.4B | 291.1B | 296B | 323.5B | 401.1B | 417.5B | 370.5B | 369.4B | 416.2B | |
| (210.6B) | (234.5B) | (232.8B) | (227.8B) | (238B) | (281.1B) | (290B) | (268B) | (256.1B) | (284.5B) | |
| 55.8B | 65.9B | 58.3B | 68.2B | 85.5B | 120.1B | 127.5B | 102.5B | 113.3B | 131.7B | |
| (53.2B) | (49.2B) | (48.2B) | (48.5B) | (46.8B) | (49.3B) | (55.2B) | (54.9B) | (67.5B) | (73.5B) | |
| (34.6B) | (33.8B) | (33.4B) | (32.3B) | (30B) | (33.5B) | (35.5B) | (34.7B) | (38.3B) | (39.7B) | |
| (14.1B) | (15.4B) | (14.8B) | (16.2B) | (16.8B) | (15.7B) | (19.7B) | (20.2B) | (27.5B) | (29.9B) | |
| (4.5B) | — | — | — | — | — | — | — | (1.7B) | (3.9B) | |
| (2m) | (1m) | (2m) | (2m) | (1m) | — | (2m) | (1m) | (1m) | (2m) | |
| 2.6B | 16.7B | 10.1B | 19.7B | 38.6B | 70.8B | 72.4B | 47.6B | 45.9B | 58.2B | |
| (343m) | 824m | 6.3B | 1.7B | 1.7B | 3.3B | 3.8B | 3.4B | 26.3B | 52.2B | |
| 187m | 146m | 158m | 194m | 258m | 280m | 370m | 710m | 1.2B | 1.4B | |
| (63.3B) | 803m | (8B) | (4.1B) | (8.7B) | (8.3B) | (4.9B) | (3.8B) | (21B) | (19.6B) | |
| 196m | 89m | 50m | 236m | 75m | (7B) | 81m | 25m | 71m | 434m | |
| 36m | 132m | 860m | (36m) | 441m | 390m | 273m | 278m | 149m | (57m) | |
| (60.8B) | 18.6B | 9.3B | 17.5B | 32.2B | 59.3B | 71.7B | 47.4B | 51.5B | 91.1B | |
| (1.8B) | (6.7B) | (5.8B) | (6B) | (6.2B) | (17.7B) | (19.3B) | (15.7B) | (17.4B) | (26.9B) | |
| (62.6B) | 11.9B | 3.6B | 11.5B | 25.9B | 41.6B | 52.4B | 31.8B | 34.1B | 64.2B | |
| (230m) | (270m) | (267m) | (207m) | (220m) | (331m) | (226m) | (259m) | (346m) | (449m) | |
| (62.8B) | 11.6B | 3.3B | 11.3B | 25.7B | 41.2B | 52.2B | 31.5B | 33.7B | 63.7B | |
| (118.06) | 20.80 | 5.91 | 20.26 | 45.98 | 73.83 | 93.43 | 56.19 | 56.55 | 107.46 |
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more
